Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,001 - 1,050 out of 9,677

Document Document Title
WO/2016/042576A1
The present invention relates to co-crystals of sofosbuvir and amino acid and process for preparation thereof. The present invention also provides pharmaceutical composition comprising said co-crystals and one or more pharmaceutically ac...  
WO/2016/041877A1
Methods for the preparation of diastereomerically pure phosphoramidate prodrugs of nucleosides, and intermediates useful for the preparation are provided. The nucleosides are useful for the treatment of hepatitis C and cancer.  
WO/2015/148580A9
This invention provides UNA oligomers for gene silencing with reduced off-target effects. The UNA oligomers can have a first strand and a second strand, each of the strands being 19-29 monomers in length, the monomers being UNA monomers ...  
WO/2016/034735A1
The present invention relates to a new, chemo-enzymatic preparation method of purine nucleosides and their deaza- and aza analogues of general formula I or pharmaceutically acceptable esters or salts thereof (I) wherein X, Y, Z and V ind...  
WO/2016/035006A1
Aspects of the present application relate to novel nucleotide analogs, their use in the preparation of nucleoside phosphoramidates, (2R)-2-deoxy-2-fluoro-2-C- methyl-D-ribofuranose compounds, their use in the preparation of nucleoside ph...  
WO/2016/034807A1
A modified nucleotide, intended for the synthesis of long chain nucleic acids by enzymatic processes, comprising a "natural" nitrogenous base or a natural nitrogenous base analogue, a ribose or deoxyribose carbohydrate, and at least one ...  
WO/2016/030546A1
Cofactor analogues for methyltransferases are disclosed. The compounds are represented by formula (I) wherein R1 is COOH or COO-; X is an organic or inorganic anion carrying one or more negative charges; Y and Y' are H, or an alkyl; R2 i...  
WO/2016/028187A1
Modified oligonucleotides that contain one or more of the phosphate groups substituted at phosphorus and methods for their synthesis are disclosed.  
WO/2016/028866A1
Provided herein are formulations, methods and substituted 2'-chloro aminopyrimidinone and pyrimidine dione compounds of Formula (I) for treating Pneumovirinae virus infections, including respiratory syncytial virus infections, as well as...  
WO/2016/023906A1
A crystalline form of sofosbuvir having an X-ray powder diffraction pattern comprising no reflection at 2-theta angles in the range of from 2.0 to 7.8 when measured at a temperature of 15 to 25 °C with Cu-Kalpha1,2 radiation having a wa...  
WO/2016/023905A1
A process for preparing crystalline form 6 of sofosbuvir according to formula (I) having an X- ray powder diffraction pattern with reflections at 2-theta values of (6.1 ± 0.2) °, (8.2 ± 0.2) °, (10.4 ± 0.2) °, (12.7 ± 0.2) °, (17...  
WO/2016/023017A1
The present disclosure relates to methods of treating AML associated with DNMT3A mutations by administering one or more DOTIL inhibitors or related pharmaceutical compositions to subjects in need thereof.  
WO/2016/022027A1
The present invention relates to a process for the modification of a glycoprotein, using a β-(1,4)-N-acetylgalactosaminyltransferase or a mutant thereof.The process comprisesthe step of contacting a glycoprotein comprising a glycan comp...  
WO/2016/020691A1
Some embodiments of the present application relate to novel modified nucleotide linkers for increasing the efficiency of nucleotide incorporation in Sequencing by Synthesis applications. Methods of preparing these modified nucleotide lin...  
WO/2016/022543A1
Provided herein are methods of increasing LPL activity or ANGTPL4 inhibition of LPL; activating LPL; treating, preventing, or ameliorating atherosclerosis; treating hypertriglyceridemia; and improving lipid profile. The methods involve t...  
WO/2016/017422A1
Disclosed are a crosslinking nucleoside and nucleotide. This nucleoside has a 2',4'-crosslinking structure, and is represented by formula (I) or (I'). An oligonucleotide containing this 2',4'-crosslinking artificial nucleotide exhibits a...  
WO/2016/016865A1
The present invention pertains to process for preparing nucleoside phosphoramidate and its intermediate. The present invention provides novel intermediate, its process for preparation and its use for the preparation of Sofosbuvir.  
WO/2016/016447A1
A process for the preparation of a compound of formula (I) including all isomers, stereoisomers, enantiomers and diastereomers thereof (I), and salts thereof; the process comprising providing a mixture comprising a compound of formula (I...  
WO/2016/012781A1
The present invention provides a process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate of Formula I in high yield and purity.  
WO/2016/014927A2
Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide ribo...  
WO/2016/008461A1
The crystalline Form Z-1 of sofosbuvir, characterized by the following diffraction peaks: 8.0; 12.3; 17.1; 19.9 and 20.8 ±0,2° 2-theta with the use of CuKα radiation, and a method of its preparation.  
WO/2016/011360A1
The present invention provides methods and compositions for enhancing efficacy of anti-hormone treatment, or for preventing cancer relapse or progression following treatment. The invention also provides methods for re-sensitizing or sens...  
WO/2015/200216A1
Disclosed herein are methods of preparing a phosphoroamidate nucleotide anal which are useful in treating diseases and/'or conditions such as viral infections.  
WO/2015/198058A1
Prodrug This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate when present as a single phosphate d...  
WO/2015/198059A1
This invention relates to pharmaceutical formulations of gemcitabine-[phenyl-benzoxy-L- alaninyl)]-phosphate, a monophosphate derivative of the well-known oncology drug gemcitabine. In particular, the invention relates to formulations wh...  
WO/2015/188782A1
The present invention relates to a method for preparing sofosbuvir. In particular, provided in the present invention is a more stereoselective preparation method. The preparation method has the advantages of a richer required isomer prep...  
WO/2015/185565A1
A compound of formula (I) or a pharmaceutically acceptable salt and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of sai...  
WO/2015/186068A1
Provided herein are crystalline beta-D-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof. The crystalline beta-D-nicot...  
WO/2015/186114A1
Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analo...  
WO/2015/181624A2
Provided herein are compounds, compositions, and methods for the treatment of cancer, including leukemia. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in...  
WO/2015/181201A1
A composition comprising a) a compound of Formula (I), where R1, R2, and R3 are, each one and independently, hydrogen or a protector group, wherein said protector group may consist of an alkyl group, a cycloalkyl group, a heterocyclic cy...  
WO/2015/176542A1
Disclosed are an adenosine derivative as represented by formula I, and synthesis preparation process and use thereof in treating hyperlipidemia, fatty liver and atherosclerosis. Particularly, disclosed is a novel compound N6-(1-(4-methox...  
WO/2015/179284A1
This disclosure is related to a method for determining the identity of a nucleotide residue of a single- stranded DNA or RNA, or sequencing DNA or RNA, in a solution using an ion-sensing field effect transistor and reversible nucleotide ...  
WO/2015/178265A1
It was discovered that interposing a suitable aromatic amidation linker in making a prodrug to serve as a γ-glutamylation drug provides stability even in a close to physiological environment, recognition by GGT, and very rapid release o...  
WO/2015/168172A1
The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, ...  
WO/2015/167620A1
The present invention generally relates to compounds that include one or more thermally labile protecting groups, compositions including the compounds, methods of making the compounds and compositions and methods of using the compounds a...  
WO/2015/167616A1
Methods and Compositions involving the administration of guanosine, identified as Toll like receptor (TLR) 2 and 4 agonists, that will be useful for enhancing the potency of vaccine and cancer immunotherapies are disclosed. Method of pre...  
WO/2015/168461A2
Aspects of the present disclosure include compositions that make use of phosphorus and/or nucleobase protecting groups which find use in the synthesis of long polynucleotides. Phosphorus protecting groups are provided that help increase ...  
WO/2015/164812A1
The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and ca...  
WO/2015/162130A1
The present disclosure provides novel compounds containing a base- modified nucleoside of formula and methods for detecting the presence of guanine in a nucleic acid and for isolating O6-alkyl guanine comprising nucleic acid. The disclos...  
WO/2015/164770A1
Colorimetry is used to detect amplification reaction products. A sample is contacted with a reaction mix under conditions such that an amplification reaction occurs and produces an amplification reaction product if the sample contains a ...  
WO/2015/164573A1
Provided are novel compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are inhibitors of CD73 and are useful in the treatment of cancer.  
WO/2015/158913A1
The present invention relates to novel phosphate-modified nucleosides, such as phosphoramidate nucleosides. The invention also relates to the use of these novel phosphate-modified nucleosides to treat or prevent viral infections and prol...  
WO/2015/161137A1
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be admi...  
WO/2015/155739A1
The present application discloses a stereoselective process for the preparation of β-C-arylglucosides that does not require the use of conventional carbohydrate protecting groups.  
WO/2015/153496A1
Disclosed are modified thymine bases that provide enhanced base-pairing affinity for adenine or 2,6-diaminopurine bases in polynucleotide hybridization complexes. Also disclosed are polynucleotide oligomers, polynucleotide hybridization ...  
WO/2015/148746A1
The present invention is directed to 4'-substituted nucleoside derivatives of Formula I (Formula I), and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, an...  
WO/2015/144282A1
The invention relates to an inorganic-organic hybrid compound as an ion compound, composed of an inorganic cation and an organic anion active substance and optionally, an organic anion fluorescent dye.  
WO/2015/148402A1
This disclosure provides systems and methods for attaching nano pore-detectable tags to nucleotides. The disclosure also provides methods for sequencing nucleic acids using the disdosed tagged nudeotides. Provided herein are nudeotides w...  
WO/2015/148522A1
This invention is about the compositions and methods for assessing and treating vascular endothelial dysfunction. Various aspects provide a method for treatment of vascular endothelial dysfunction, comprising administering a composition ...  

Matches 1,001 - 1,050 out of 9,677